Weekly Recap | Amgen +7.51%, Phase 3 Sjogren's trial hits endpoint
I'm LongbridgeAI, I can summarize articles.Amgen rallied 7.51% this week to close at $414.61, up from $385.65 the previous Friday. The S&P 500 gained 1.21%, so the stock beat the benchmark by about 6.3 percentage points. Monday opened lower and closed at $393.16, Tuesday gapped higher to $410.24, and the following three sessions traded in a $404-415 range before Friday ended near the week’s high. The close sat above both the 20-day moving average of $404.90 and the 60-day average of $398.07.
The Week
Amgen rallied 7.51% this week to close at $414.61, up from $385.65 the previous Friday. The S&P 500 gained 1.21%, so the stock beat the benchmark by about 6.3 percentage points. Monday opened lower and closed at $393.16, Tuesday gapped higher to $410.24, and the following three sessions traded in a $404-415 range before Friday ended near the week’s high. The close sat above both the 20-day moving average of $404.90 and the 60-day average of $398.07.
Key Events
The week’s main story was the Phase 3 readout for dazodalibep in Sjogren’s disease. Shares jumped about 4.4% in pre-market trading on 22 September and closed up 3.90% that day. The trial met its primary endpoint, but regulatory filing still depends on data from another trial, so the stock consolidated in the following sessions. Broader coverage touched on weight-loss drug competition and healthcare value-chain reshuffling, but the company-specific focus stayed on the single pipeline result.
Analyst Ratings
As of 24 September, 34 brokers covered Amgen: 8 rated it buy, 4 overweight, 17 hold, 2 underweight, and 3 sell. The consensus rating is hold, with a consensus target of $389.22, about 6.1% below the latest price of $414.61. Targets range from $225 to $457, showing wide dispersion. Amgen ranks second by rating among 506 biotech names.
The Week Ahead
Next week brings a stack of macro data: the Dallas Fed manufacturing index on 28 September, then FHFA house prices, Case Shiller 20-city home prices, JOLTS job openings, and consumer confidence on 29 September. No company earnings are scheduled, but the second trial dataset needed for the Sjogren’s filing remains a potential catalyst.
In Short
This week’s rally ran alongside a single late-stage pipeline result, yet the consensus target sits below spot and the latest session’s flow showed large-lot money as a net seller while medium and small lots were net buyers. Valuation stands at 25.64x P/E and 19.18x P/B. The next leg depends on whether the second trial data supports a regulatory filing, and on how the macro calendar shifts risk appetite across biotech.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.